image credit: Adobe Stock

Novartis buys a preclinical biotech and its RNA drug technology

July 17, 2023


Novartis said it was drawn to DTx for multiple reasons, interested in both the biotech’s lead treatment for Charcot-Marie-Tooth as well as its capabilities with small, interfering RNA — a technology with which the pharma is already familiar.

Small, interfering RNA, or siRNA, drugs work by disrupting the way cells translate DNA into proteins. SiRNA drugs can obstruct this process, preventing or limiting the production of specific proteins involved in disease.

Read More on Biopharma Dive